Publication details
Ticagrelor a studie PLATO
Title in English | Ticagrelor and PLATO study |
---|---|
Authors | |
Year of publication | 2011 |
Type | Article in Periodical |
Magazine / Source | Kardiologická revue |
MU Faculty or unit | |
Citation | |
Field | Cardiovascular diseases incl. cardiosurgery |
Keywords | ticagrelor; PLATO; antiaggregation; myocardial infarction |
Description | Ticagrelor is an oral, reversible, direct P2Y12 adenosine diphosphate (ADP) receptor antagonist with faster onset of action and more pronounced antiplatelet activity than clopidrogel. It was tested in a large multicentric PLATO study (180 mg loading dose, 90 mg twice daily maintenance dose) against clopidrogel (300–600 mg loading dose, 75 mg maintenance dose) in 18,624 patients with acute coronary syndrome with or without ST elevations. After 12 months, composite of cardiovascular death, heart attack and stroke occurred in 9.8% patients treated with ticagrelorem compared to 11.7% of patients on clopidrogel (p < 0.001). Heart attack alone occurred in 5.8% of patients on ticagrelor compared to 6.9% of patients on clopidrogel (p = 0.005), cardiovascular death occurred in 4.0% vs. 5.1% (p = 0.001) and stroke in 1.5% vs. 1.3% (p = 0.22). No difference was observed in the incidence of large bleeding (11.6% vs. 11.2%, p = 0.43). |